Investigating heart damage from thoracic radiotherapy in lung cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The LOCATION MATTERS study aims to explore the impact of thoracic radiotherapy on heart health in patients with locally advanced lung non-small cell carcinoma. Participants will undergo a series of assessments, including ultrasound exams, CT scans, and wearable device monitoring, to evaluate the relationship between radiation dose to heart substructures and cardiovascular outcomes. The study will track changes in cardiac function and structure at baseline, after treatment, and at nine months post-treatment. By identifying radiosensitive biomarkers, the research seeks to improve patient safety and treatment efficacy.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patients with NSCLC
* Patients with locally advanced disease (Stage 3)
* Patients treated with RT at Fondazione IRCCS Istituto Nazionale dei Tumori

Exclusion Criteria:

* Previous thoracic radiotherapy
* Previous heart surgery

Where it's running

• Fondazione IRCCS Istituto Nazionale dei Tumori
  Milan, Italy Recruiting

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Combining sotorasib and trastuzumab deruxtecan for advanced KRAS G12C non-small cell lung cancer

  This trial tests whether giving sotorasib with trastuzumab deruxtecan is safe and can shrink tumors or slow progression in people with locally advanced or metastatic non-small cell lung cancer that has a KRAS G12C mutation and progressed after prior targeted therapy, immunotherapy, and chemotherapy.

  Recruiting at 9 sites Phase 1/2 National Cancer Institute (NCI) · Sacramento, California and 8 other locations · NCT07012031

• Adding high dose targeted radiation to usual treatment for advanced lung cancer

  This study is testing if adding a high dose of targeted radiation to the usual chemotherapy and immunotherapy can help people with advanced lung cancer live longer and feel better.

  Recruiting at 446 sites Phase 3 NRG Oncology · Birmingham, Alabama and 476 other locations · NCT05624996

• Personalized vaccine combined with pembrolizumab for advanced solid tumors

  This study is testing a new personalized cancer vaccine combined with pembrolizumab to see if it helps people with advanced solid tumors fight their cancer better.

  Recruiting Phase 1/2 Mayo Clinic · Jacksonville, Florida · NCT05269381

• Using papaverine with chemoradiation to treat advanced non-small cell lung cancer

  This study is testing the best dose of papaverine combined with chemotherapy and radiation to see if it helps people with advanced non-small cell lung cancer live longer and control their tumors better.

  Recruiting at 2 sites Phase 1 Ohio State University Comprehensive Cancer Center · Duarte, California and 1 other locations · NCT05136846

• Assessing heart health in lung cancer patients receiving personalized chemoradiation

  This study is testing how personalized chemoradiation treatment for lung cancer affects heart health in patients and if adjusting the treatment can help reduce heart disease risk.

  Recruiting M.D. Anderson Cancer Center · Houston, Texas · NCT05010109

• Neoadjuvant PD-L1/VEGF Bispecific Antibody with Chemo versus Chemo plus PD-1 Monoclonal Antibody in Locally Advanced NSCLC

  In people with locally advanced NSCLC, this study tests whether adding a PD-L1/VEGF bispecific antibody to chemotherapy before surgery improves outcomes compared with a PD-1 antibody added to chemotherapy.

  Recruiting at 2 sites Phase 3 Shanghai Pulmonary Hospital, Shanghai, China · Shanghai, China and 4 other locations · NCT07863999

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.